121 related articles for article (PubMed ID: 38539051)
1. High frequency of circulating non-classical monocytes is associated with stable remission in relapsing-remitting multiple sclerosis.
Minote M; Sato W; Kimura K; Kimura A; Lin Y; Okamoto T; Takahashi R; Yamamura T
Immunol Med; 2024 Mar; ():1-15. PubMed ID: 38539051
[TBL] [Abstract][Full Text] [Related]
2. No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon.
Zafar A; AlShamrani FJG
Mult Scler Relat Disord; 2021 Jun; 51():102875. PubMed ID: 33691260
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
Perumal J; Balabanov R; Su R; Chang R; Balcer L; Galetta S; Campagnolo DI; Avila R; Lee L; Rutledge D; Fox RJ
Adv Ther; 2021 Jul; 38(7):3724-3742. PubMed ID: 34014549
[TBL] [Abstract][Full Text] [Related]
4. Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN.
Newsome SD; Scott TF; Arnold DL; Altincatal A; Naylor ML
Mult Scler Relat Disord; 2022 Jan; 57():103367. PubMed ID: 35158473
[TBL] [Abstract][Full Text] [Related]
5. Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?
Uher T; Havrdova E; Sobisek L; Krasensky J; Vaneckova M; Seidl Z; Tyblova M; Ramasamy D; Zivadinov R; Horakova D
Mult Scler; 2017 Feb; 23(2):242-252. PubMed ID: 27230790
[TBL] [Abstract][Full Text] [Related]
6. Inclusion of the Symbol Digit Modalities Test in a revised assessment of 'no evidence of disease activity-4 (NEDA-4)' in Latin-American patients with multiple sclerosis.
Guevara C; Villa E; Diaz V; Garrido C; Martinez M; Orellana P; Alarcón P; Silva-Rosas C; Barker GJ; Kempton MJ; de Grazia J
Mult Scler Relat Disord; 2020 Jul; 42():102076. PubMed ID: 32361478
[TBL] [Abstract][Full Text] [Related]
7. No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany.
Huhn K; Senger D; Utz KS; Schmidt M; Fröhlich K; Waschbisch A; Seifert F; Dörfler A; Lee DH; Linker RA
Mult Scler Relat Disord; 2019 Jan; 27():133-138. PubMed ID: 30384198
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
[TBL] [Abstract][Full Text] [Related]
9. Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis.
Arnold DL; Shang S; Dong Q; Meergans M; Naylor ML
Ther Adv Neurol Disord; 2018; 11():1756286418795085. PubMed ID: 30181780
[TBL] [Abstract][Full Text] [Related]
10. miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod.
Gonzalez-Martinez A; Patel R; Healy BC; Lokhande H; Paul A; Saxena S; Polgar-Turcsanyi M; Weiner HL; Chitnis T
J Neuroinflammation; 2023 May; 20(1):131. PubMed ID: 37254147
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of 2-year "No evidence of disease activity" (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study.
Bazzurri V; Fiore A; Curti E; Tsantes E; Franceschini A; Granella F
Mult Scler Relat Disord; 2023 Nov; 79():105015. PubMed ID: 37769430
[TBL] [Abstract][Full Text] [Related]
12. Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis.
Rotstein D; Solomon JM; Sormani MP; Montalban X; Ye XY; Dababneh D; Muccilli A; Saab G; Shah P
Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36224046
[TBL] [Abstract][Full Text] [Related]
13. Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years.
Guerra T; Caputo F; Orlando B; Paolicelli D; Trojano M; Iaffaldano P
Neurol Sci; 2021 Nov; 42(11):4647-4655. PubMed ID: 33677753
[TBL] [Abstract][Full Text] [Related]
14. Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
Szilasiová J; Mikula P; Rosenberger J; Fedičová M; Gdovinová Z; Urban P; Frigová L
Mult Scler; 2021 Nov; 27(13):2023-2030. PubMed ID: 33635154
[TBL] [Abstract][Full Text] [Related]
15. NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
Sormani MP; Muraro PA; Saccardi R; Mancardi G
Mult Scler; 2017 Feb; 23(2):201-204. PubMed ID: 27207454
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
[TBL] [Abstract][Full Text] [Related]
17. Association of No Evidence of Disease Activity With No Long-term Disability Progression in Multiple Sclerosis: A Systematic Review and Meta-analysis.
Rotstein D; Solomon JM; Sormani MP; Montalban X; Ye XY; Dababneh D; Muccilli A; Shah P
Neurology; 2022 Jul; 99(2):e209-e220. PubMed ID: 35473761
[TBL] [Abstract][Full Text] [Related]
18. Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the "no evidence of disease activity" parameter.
Pato Pato A; Costa Arpín E; Rodríguez Regal A; Rodríguez Constenla I; Cimas Hernando I; Muñoz Pousa I; Naya Ríos L; Lorenzo González JR; Amigo Jorrín MC; Prieto González JM
Neurologia (Engl Ed); 2021 Jun; 36(5):346-352. PubMed ID: 34714232
[TBL] [Abstract][Full Text] [Related]
19. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
